Average Co-Inventor Count = 5.77
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Boehringer Ingelheim International Gmbh (29 from 1,536 patents)
2. Centrexion Therapeutics Corporation (5 from 36 patents)
34 patents:
1. 12351584 - Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
2. 12209094 - CCR2 receptor antagonists and uses thereof
3. 11731981 - CCR2 receptor antagonists and uses thereof
4. 11691977 - Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide
5. 11179371 - Triazole benzamide derivatives as GPR142 agonists
6. 11046706 - CCR2 receptor antagonists and uses thereof
7. 10875867 - Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
8. 10640486 - Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
9. 10501440 - Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
10. 10479794 - Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
11. 10399961 - Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
12. 10196402 - CCR2 receptor antagonists and uses thereof
13. 10023575 - Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
14. 9981954 - 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors
15. 9920035 - Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof